125 related articles for article (PubMed ID: 10903401)
1. Applications of gene transfer to targeted radiotherapy.
Mairs RJ; Cunningham SH; Boyd M; Carlin S
Curr Pharm Des; 2000 Sep; 6(14):1419-32. PubMed ID: 10903401
[TBL] [Abstract][Full Text] [Related]
2. Gene manipulation to enhance MIBG-targeted radionuclide therapy.
Mairs RJ; Fullerton NE; Cosimo E; Boyd M
Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651
[TBL] [Abstract][Full Text] [Related]
3. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
5. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
[TBL] [Abstract][Full Text] [Related]
6. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
[TBL] [Abstract][Full Text] [Related]
7. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
8. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
[TBL] [Abstract][Full Text] [Related]
9. Radiation physics and genetic targeting: new directions for radiotherapy. The Douglas Lea Lecture 1999.
Wheldon TE
Phys Med Biol; 2000 Jul; 45(7):R77-95. PubMed ID: 10943913
[TBL] [Abstract][Full Text] [Related]
10. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
[TBL] [Abstract][Full Text] [Related]
11. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
12. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
14. Genetic enhancement of radionuclide cancer therapy.
Wheldon TE; Mairs RJ; Boyd M
Lancet; 1999 Dec; 354(9194):1999-2000. PubMed ID: 10622325
[No Abstract] [Full Text] [Related]
15. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
[TBL] [Abstract][Full Text] [Related]
16. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
17. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
18. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
19. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
Armour A; Cunningham SH; Gaze MN; Wheldon TE; Mairs RJ
Br J Cancer; 1997; 75(4):470-6. PubMed ID: 9052395
[TBL] [Abstract][Full Text] [Related]
20. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
